Analysed INNOVENT BIOLOGICS INC (IVBXF:OTCMKTS) News Sources
Innovent Biologics (SEHK:1801) Stock Still Looks Below Fair Value As Shares Rose 153%
29-09-2026
yahoo.com
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
09-10-2026
yahoo.com
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
23-10-2026
yahoo.com
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
25-10-2026
yahoo.com
2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
25-10-2026
yahoo.com
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
26-10-2026
yahoo.com
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
26-10-2026
yahoo.com
What is the current price of INNOVENT BIOLOGICS INC (IVBXF:OTCMKTS)?
The current price of INNOVENT BIOLOGICS INC (IVBXF:OTCMKTS) is $9.9.
INNOVENT BIOLOGICS INC (IVBXF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of INNOVENT BIOLOGICS INC (IVBXF:OTCMKTS) since the previous trading day is $-1.4.
INNOVENT BIOLOGICS INC (IVBXF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of INNOVENT BIOLOGICS INC (IVBXF:OTCMKTS) since the previous trading day is -12.3894%.
What is the most recent average sentiment score for INNOVENT BIOLOGICS INC (IVBXF:OTCMKTS)?
The most recent average sentiment score for INNOVENT BIOLOGICS INC (IVBXF:OTCMKTS) is 75 out of 100.
What is the most recent average sentiment for INNOVENT BIOLOGICS INC (IVBXF:OTCMKTS)?
The most recent sentiment for INNOVENT BIOLOGICS INC (IVBXF:OTCMKTS) is .
SEC-8K** Filing Available For INNOVENT BIOLOGICS INC (IVBXF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.